CTOs on the Move

Ancient Nutrition

www.ancientnutrition.com

 
At Ancient Nutrition, our mission is to restore our health, strength and vitality by providing history`s healthiest whole food nutrients to the modern world.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Ancient Nutrition raised $103M on 03/08/2018

Similar Companies

Biotechnology Council of New Jersey

Biotechnology Council of New Jersey, Inc. is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southern Wake Family Medicine

Southern Wake Family Medicine is a Fuquay Varina, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Conval-Aid

Conval-Aid is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dynamic Medical Systems, Inc

Dynamic Medical Systems is a recognized leader in providing products and services for the healthcare industry.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic